Targeting mutant p53 in cancer: the latest insights

被引：19
|
作者：
Di Agostino, Silvia [1 ]
Fontemaggi, Giulia [1 ]
Strano, Sabrina [1 ]
Blandino, Giovanni [1 ]
D'Orazi, Gabriella [2 ,3 ]
机构：
[1] IRCCS Regina Elena Natl Canc Inst, Dept Res Diag & Innovat Technol, Oncogen & Epigenet Unit, I-00144 Rome, Italy
[2] Univ G DAnnunzio, Dept Med Sci, I-66013 Chieti, Italy
[3] IRCCS Regina Elena Natl Canc Inst, Dept Res Adv Diagnost & Innovat Technol, Unit Cellular Networks & Mol Therapeut Targets, I-00144 Rome, Italy
来源：
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2019年 / 38卷 / 1期
关键词：
p53; Li-Fraumeni; Small molecules; Mutant p53 reactivation; Exosomes; miRNA; Cancer-associated fibroblasts;
D O I：
10.1186/s13046-019-1302-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This commentary wishes to highlight the latest discoveries in the mutant p53 field that have been discussed in the 8th p53 Mutant Workshop 2019, held in Lyon. TP53 mutant (mutp53) proteins are involved in the pathogenesis of most human cancers. Mutp53 proteins not only lose wild-typ53 function but, in some circumstances, may acquire novel oncogenic functions, namely gain-of-function (GOF), which lead to aberrant cell proliferation, chemoresistance, disruption of tissue architecture, migration, invasion and metastasis. Decoding the TP53 mutational spectrum and mutp53 interaction with additional transcription factors will therefore help to developing and testing novel and hopefully more efficient combinatorial therapeutic approaches.
引用
收藏
页数：3
相关论文
共 50 条
  • [31] The role of mutant p53 in human cancer
    Goh, Amanda M.
    Coffill, Cynthia R.
    Lane, David P.
    [J]. JOURNAL OF PATHOLOGY, 2011, 223 (02): : 116 - 126
  • [32] CANCER Mutant p53 and chromatin regulation
    Prives, Carol
    Lowe, Scott W.
    [J]. NATURE, 2015, 525 (7568) : 199 - 200
  • [33] Mutant p53 as a guardian of the cancer cell
    Mantovani, Fiamma
    Collavin, Licio
    Del Sal, Giannino
    [J]. CELL DEATH AND DIFFERENTIATION, 2019, 26 (02): : 199 - 212
  • [34] Mutant p53 as a target for cancer treatment
    Duffy, Michael J.
    Synnott, Naoise C.
    Crown, John
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 83 : 258 - 265
  • [35] Mutant p53 as an Antigen in Cancer Immunotherapy
    Sobhani, Navid
    D'Angelo, Alberto
    Wang, Xu
    Young, Ken H.
    Generali, Daniele
    Li, Yong
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11) : 1 - 21
  • [36] Mutant p53 as a guardian of the cancer cell
    Fiamma Mantovani
    Licio Collavin
    Giannino Del Sal
    [J]. Cell Death & Differentiation, 2019, 26 : 199 - 212
  • [37] The benefits of Didox in triple negative breast cancer treatment targeting mutant p53
    Sultana, Nahid
    Wilson, Elizabeth A.
    Shah, Khyati N.
    Elford, Howard L.
    Faridi, Jesika S.
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [38] Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
    Zhang, Shengliang
    Carlsen, Lindsey
    Hernandez Borrero, Liz
    Seyhan, Attila A.
    Tian, Xiaobing
    El-Deiry, Wafik S.
    [J]. BIOMOLECULES, 2022, 12 (04)
  • [39] A Chimeric p53 Evades Mutant p53 Transdominant Inhibition in Cancer Cells
    Okal, Abood
    Mossalam, Mohanad
    Matissek, Karina J.
    Dixon, Andrew S.
    Moos, Philip J.
    Lim, Carol S.
    [J]. MOLECULAR PHARMACEUTICS, 2013, 10 (10) : 3922 - 3933
  • [40] Targeting p53 as a promising therapeutic option for cancer by re-activating the wt or mutant p53's tumor suppression
    Wesierska-Gadek, Jozefa
    [J]. FUTURE MEDICINAL CHEMISTRY, 2018, 10 (07) : 755 - 777
12345